Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

Clicks: 308
ID: 274199
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #28 of 83 articles by views in The Journal of antimicrobial chemotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This systematic review found little published evidence to support an optimal dosage regimen or TDM targets for amikacin therapy. The use of alternative approaches, such as consensus opinion and a review of current practice, will be required to develop guidelines to maximize therapeutic outcomes and …
Reference Key
a2016theamikacin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jenkins A;Thomson AH;Brown NM;Semple Y;Sluman C;MacGowan A;Lovering AM;Wiffen PJ; ;;
Journal The Journal of antimicrobial chemotherapy
Year 2016
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/27494904
Keywords
systematic review National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult anti-bacterial agents / therapeutic use anti-bacterial agents / administration & dosage* dose-response relationship drug drug-related side effects and adverse reactions amikacin / adverse effects* anti-bacterial agents / adverse effects* drug monitoring* amikacin / therapeutic use amikacin / administration & dosage* anti-bacterial agents / blood amikacin / blood investigators=[] affs=[]) pmid:27494904 doi:10.1093/jac/dkw250 abi jenkins alison h thomson collabauthor(name='(bsac working party on therapeutic drug monitoring)' interrupted time series analysis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.